Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03816111
Other study ID # AKTN 17.03
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date July 22, 2019
Est. completion date April 30, 2025

Study information

Verified date April 2024
Source The University of Queensland
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

For many patients peritoneal dialysis (PD) is the preferred form of dialysis to treat kidney disease as it provides greater flexibility and the ability to dialyse at home. However, PD use in Australia has been decreasing over the last 10 years. A big reason for this drop is the risk of infection. The best way to prevent PD related infections is to make sure that patients have good training in PD techniques. The researchers of this study have developed TEACH-PD, a new education package for training both PD nurses and PD patients. The aim of this study is to find out whether TEACH-PD training reduces the number of PD related infections.


Description:

End stage kidney disease is fatal unless treated with dialysis or transplant. Peritoneal dialysis (PD) is a core dialysis modality offering home-based care for patients. PD utilization is frequently threatened beyond 5 years for most patients due to PD-related infections. Patient training is a critical cornerstone of mitigating infection risk and maximizing PD durability (technique survival), but training practices are characterized by a lack of standardization and severe heterogeneity. There is no high-level evidence to inform PD training. Accordingly, a structured program encompassing how and what to teach PD patients at the inception of PD treatment has the potential to reduce serious PD-related infections, extend the longevity of PD, support cost-effective home-based dialysis care, and reduce costs and health service utilization associated with hospitalization and transition to haemodialysis. TEACH-PD is a standardised modular curriculum for both PD nurse trainers and patients that has been collaboratively developed by renal nurses, doctors, educationalists and patients, aligned to current International Society for Peritoneal Dialysis (ISPD) guidelines, utilizing modern adult learning principles. The TEACH-PD program is feasible and acceptable, as demonstrated in a successful pilot study. The primary objective of TEACH-PD CRCT (Targeted Education ApproaCH to improve Peritoneal Dialysis outcomes - a Cluster Randomised Controlled Trial) is to determine whether implementation of standardised training modules based on ISPD guidelines targeting both PD trainers and patients results in a longer time to the composite end-point of exit site infections, tunnel infections and peritonitis in incident PD patients compared to existing training practices. TEACH-PD is a registry-based, pragmatic, multi-center, multinational trial, randomising PD units to implementing TEACH-PD training modules targeted at PD trainers and incident PD patients versus standard existing practices. An estimated 1,500 patient new to PD will be recruited from at least approximately 42-44 PD units in Australia and New Zealand.The study is being coordinated by the University of Queensland (operating through the Australasian Kidney Trial Network). The TEACH-PD training modules have been developed by a core group of renal nurses from the HOME Network in conjunction with senior medical clinicians from the Australasian Kidney Trials Network, eLearning curriculum developers, consumer representatives, and education experts, in line with the ISPD guidelines, utilizing modern adult learning principles and best practice eLearning techniques. The modules will be implemented at PD units in Australia and New Zealand to formally evaluate whether, compared with standard care, a standardised training curriculum will reduce the rate of PD-related infections and improve technique survival, resulting in better outcomes for patients receiving PD and significant cost-savings to the community.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 1500
Est. completion date April 30, 2025
Est. primary completion date March 30, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients new to PD; - Patients > 18 years of age, - Need to undergo PD training; - Are able to provide informed consent

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
TEACH-PD Training Curriculum
The TEACH-PD training modules have been developed by a core group of renal nurses from the HOME Network in conjunction with senior medical clinicians from the Australasian Kidney Trials Network, eLearning curriculum developers, consumer representatives, and education experts, in line with the International Society for Peritoneal Dialysis guidelines, utilizing modern adult learning principles and best practice eLearning techniques.
Current standard PD training
Current PD training materials and plan

Locations

Country Name City State
Australia Royal Adelaide Hospital Adelaide South Australia
Australia Princess Alexandra Hospital Brisbane Queensland
Australia Cairns Hospital Cairns Queensland
Australia Canberra Hospital Canberra Australian Capital Territory
Australia Monash Health Dandenong Victoria
Australia St Vincent's Hospital Sydney Darlinghurst New South Wales
Australia Royal Darwin Hospital Darwin Northern Territory
Australia St Vincent's Hospital Melbourne Fitzroy Victoria
Australia Barwon Health Geelong Victoria
Australia Gosford Hospital Gosford New South Wales
Australia Austin Health Heidelberg Victoria
Australia Royal Brisbane and Women's Hospital Herston Queensland
Australia Royal Hobart Hospital Hobart Tasmania
Australia Launceston General Hospital Launceston Tasmania
Australia Lismore Hospital Lismore New South Wales
Australia Mackay Base Hospital Mackay Queensland
Australia Logan Hospital Meadowbrook Queensland
Australia Royal Melbourne Hospital Melbourne Victoria
Australia Fiona Stanley Hospital Murdoch Western Australia
Australia Sunshine Coast University Hospital Nambour Queensland
Australia Sir Charles Gairdner Hospital Nedlands Western Australia
Australia Orange Hospital Orange New South Wales
Australia Royal Perth Hospital Perth Western Australia
Australia Gold Coast University Hospital Southport Queensland
Australia Royal North Shore Hospital St Leonards New South Wales
Australia Liverpool Hospital Sydney New South Wales
Australia Nepean/Blacktown Hospital Sydney New South Wales
Australia Prince of Wales Hospital Sydney New South Wales
Australia Royal Prince Alfred/Concord Hospital Sydney New South Wales
Australia St George Hospital Sydney New South Wales
Australia Tamworth Hospital Tamworth New South Wales
Australia Toowoomba Hospital Toowoomba Queensland
Australia The Tweed Hospital Tweed Heads New South Wales
New Zealand Auckland Hospital Auckland
New Zealand Middlemore Hospital Auckland
New Zealand North Shore Hospital Auckland
New Zealand Waitakere Hospital Auckland
New Zealand Wairau Hospital Blenheim
New Zealand Christchurch Hospital Christchurch
New Zealand Dunedin Hospital Dunedin
New Zealand Gisborne Hospital Gisborne
New Zealand Waikato Hospital Hamilton
New Zealand Hawke's Bay Hospital Hastings
New Zealand Nelson Hospital Nelson
New Zealand Taranaki Hospital New Plymouth
New Zealand Palmerston North/Whanganui Hospital Palmerston North
New Zealand Wellington Hospital Wellington
New Zealand Whangarei Hospital Whangarei

Sponsors (4)

Lead Sponsor Collaborator
The University of Queensland Australia and New Zealand Dialysis and Transplant Registry, New Zealand Peritoneal Dialysis Registry, The HOME Network

Countries where clinical trial is conducted

Australia,  New Zealand, 

Outcome

Type Measure Description Time frame Safety issue
Other Life participation questionnaire Life participation measured using PROMIS (patient-reported outcomes measurement information system) Short Form - Ability to participate in social roles and activities 6a. PROMIS will measure 6 dimensions (trouble with leisure activities, trouble doing family activities, trouble doing work, trouble doing activities with friends, limiting fun with others and limiting activities with friends). Each dimension has 5 measurement levels: Always (1), Usually, (2), Sometimes (3), Rarely (4) and Never (5). Completed at baseline and 24 months
Primary Time to the first occurrence of any PD-related infection Time to the first occurrence of any PD-related infection including exit site infection, tunnel infection or peritonitis From the PD start date until first PD-related infection, assessed up to 4 years
Secondary Time to first exit site infection Time to first exit site infection From the PD start date until first exit site infection, assessed up to 4 years
Secondary Time to first tunnel infection Time to first tunnel infection From the PD start date until first tunnel infection, assessed up to 4 years
Secondary Time to first episode of peritonitis Time to first episode of peritonitis From the PD start date until first peritonitis episode, assessed up to 4 years
Secondary Time to infection-associated catheter removal Time to infection-associated catheter removal From the PD start date until first infection-associated catheter removal, assessed up to 4 years
Secondary Incidence of technique failure - 30 days Incidence of technique failure defined as transfer to haemodialysis for greater than 30-days and/or death within this time Assessed at 30 days after transfer to HD or if death occurs within this period
Secondary Incidence of technique failure - 180 days Incidence of technique failure defined as transfer to haemodialysis for greater than 180-days and/or death within this time Assessed at 180 days after transfer to HD or if death occurs within this period
Secondary Incidence of all-cause hospitalization Incidence of all-cause hospitalization collected via health department hospitalization data linkage Assessed from the PD start date, over up to 4 years
Secondary Incidence of all-cause mortality Incidence of all-cause mortality Assessed from the PD start date, over up to 4 years
Secondary Participant Quality of Life questionnaire Participant-reported Quality of Life measured using EQ-5D-5L (EuroQol-5 dimensions questionnaire). EQ-5D-5L measures quality of life using 2 methods - a descriptive scale and a Visual Analogue Scale. The descriptive scale comprises 5 dimensions (mobility, self care, usual activities, pain/discomfort, anxiety/ depression). Each dimension has 5 measurement levels: no problems (1), slight problems (2), moderate problems (3), severe problems (4), and extreme problems (5). Numbers associated with levels can be used to report an index score.
The VAS records the respondent's self-rated health on a 20 cm vertical, visual analogue scale with endpoints labelled 'the best health you can imagine' (100) and 'the worst health you can imagine' (0).
Completed at baseline, 6, 12, 18 and 24 months
Secondary Health-care cost-effectiveness analysis Difference in the incremental cost per Quality Adjusted Life Years gained between treatment arms Assessed from the PD start date, over up to 4 years
See also
  Status Clinical Trial Phase
Completed NCT03907657 - Contrast-enhanced Ultrasound as a Screening Tool for Kidney Cancer in Patients With Von-Hippel Lindau Phase 2
Not yet recruiting NCT06223750 - Virtual Kidney Check and Follow-up N/A
Completed NCT02468401 - Prevention of Contrast Induced Nephropathy in Patients With Advanced Renal Dysfunction Undergoing Coronary Interventions N/A
Completed NCT02238067 - Survey on Anemia Therapy in Patients With Chronic Kidney Disease Not on Dialysis N/A
Completed NCT01194154 - A Study of Methoxy Polyethylene Glycol-epoetin Beta (Mircera) in Participants With Chronic Kidney Disease (PRIMAVERA) Phase 2
Completed NCT02263833 - An Observational, Prospective, Safety Study of Mircera (Monopegylated Epoetin Beta) in Clinical Practice N/A
Active, not recruiting NCT04078750 - PLATO - Medication Adherence in Transplant Recipients N/A
Recruiting NCT05490511 - Drug-gene-nutraceutical Interactions of Cannabidiol and Tacrolimus Phase 1
Terminated NCT05747053 - Personalization of Immunosuppressive Treatment for Organ Transplant Recipients
Completed NCT03189212 - Feasibility Study of Telemedicine for Dialysis Patients Awaiting Transplantation N/A
Enrolling by invitation NCT05374291 - The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD Phase 3
Recruiting NCT05033054 - Effect of SGLT2i on Cardiovascular Biomarkers in Patients With Type 2 Diabetes and CKD Stage 3b-4
Completed NCT05064267 - Hemostatic Profiles in Pediatric CKD
Not yet recruiting NCT06069518 - Continuous Glucose Monitoring in Patients With Diabetes on Peritoneal Dialysis
Not yet recruiting NCT03590067 - Oral Findings in a Group of Egyptian Pediatric Patients at Endstage Renal Disease
Recruiting NCT04014127 - Coronary Microvascular Dysfunction in Chronic Kidney Disease
Recruiting NCT04626323 - Randomized Study Comparing Metabolic Surgery With Intensive Medical Therapy to Treat Diabetic Kidney Disease Phase 2
Not yet recruiting NCT05774392 - An Observational Study of Patients With Chronic Kidney Disease
Not yet recruiting NCT06343727 - A High Protein Egg White Pudding for People With Kidney Failure (HiPE KF) N/A
Completed NCT04515797 - QUICKly Eradicate Hepatitis C in Patients Undergoing REnal Transplant With 4 Weeks of Glecaprevir/Pibrentasvir Phase 4